Abstract
The rate of perinatal HIV transmission has decreased significantly in developed countries. However, worldwide, it remains the main source of HIV infection within the pediatric population. Recent advances as a result of findings from clinical trials, viral resistance testing and the advent of new drugs have increased the options for initial treatment regimens. This article provides an overview of antiretroviral therapy in treatment-naive children, including recent pediatric data and updated guidelines from the NIH. It also provides information on new drugs approved for the pediatric age group, dosage information, drug resistance testing and monitoring suggestions for children and adolescents receiving antiretroviral therapy. Special issues pertaining to adherence, disclosure and contraception are also highlighted.
| Original language | English |
|---|---|
| Pages (from-to) | 1381-1402 |
| Number of pages | 22 |
| Journal | Expert Review of Anti-Infective Therapy |
| Volume | 8 |
| Issue number | 12 |
| DOIs | |
| State | Published - Dec 2010 |
| Externally published | Yes |
Keywords
- adherence
- antiretroviral therapy
- drug resistance
- non-nucleoside reverse transcriptase inhibitor
- nucleoside reverse transcriptase inhibitor
- pediatric HIV infection
- protease inhibitor
Fingerprint
Dive into the research topics of 'Pediatric antiretroviral therapy'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver